Sanofi SA SNY on Tuesday reported Phase 2 data for its experimental therapy lunsekimig in chronic respiratory diseases, ...

Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP The AIRCULES phase 2b study achieved its primary and key secondary endpoints in moderate ...

Add Yahoo as a preferred source to see more of our stories on Google. Chronic snores can be a sign of polyps in the nose, a condition thought to affect around 5% of people. Christin Klose/dpa An ...

Two of Sanofi’s lunsekimig Phase II trials have met their primary endpoints in respiratory disease, while a study in atopic ...

Constantly congested? The culprit could be nasal polyps, noncancerous growths that leave your nose stuffed and your sense of smell stymied. We asked a top ear, nose and throat specialist to tell us ...

The nose is the subject of many sayings. A measurement could be on the nose or an object be right under your nose. You may be reminded to keep your nose clean and keep it out of another's affairs.

Spring allergy season can be a double problem for some people. On top of allergies, they also have blocked sinuses, and surgery may be the only path to relief. Allergy sufferers are most at risk of ...

The nose is the subject of many sayings. A measurement could be on the nose or an object right under your nose. You may be reminded to keep your nose clean and out of another’s affairs. While often ...

The FDA broadened dupilumab's (Dupixent) approval as an add-on maintenance treatment for chronic rhinosinusitis with nasal polyps to include adolescents as well, Regeneron Pharmaceuticals and Sanofi ...

SAN DIEGO -- Tezepelumab (Tezspire) reduced nasal polyps and symptoms in severe chronic rhinosinusitis while also decreasing need for further treatments, the WAYPOINT trial showed. The monoclonal ...

Sanofi’s lunsekimig meets primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP: Paris Wednesday, April 8, 2026, 09:00 Hrs [IST] Phase 2 studie ...